Drugs / EXOB-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06279741 | Dec 2023 → Jan 2027 expected | bronchopulmonary dysplasia | EXO Biologics S.A. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EXOB-001 | “The phase 1/2 trial aims to evaluate the safety and efficacy of EXOB-001 consisting of extracellular vesicles derived from umbilical cord mesenchymal stromal cells in the...” NCT06279741 ↗ |
| Modality | Other / unclassified | “EXOB-001 consisting of extracellular vesicles derived from umbilical cord mesenchymal stromal cells” NCT06279741 ↗ |
| Route | Other | “via the endotracheal route” NCT06279741 ↗ |